Charles Hu

Charles Hu has experience as a CEO of Ryoden Medical Holdings. Their background also includes work at Ryoden Development Limited, Incando Therapeutics, Cere Ventures Ltd, City University Of Hong Kong, Asian Fund For Cancer Research Limited, HKBIO, Hong Kong Trade Development Council, Hong Kong Professionals And Senior Executives Association, Innovation And Technology Commission, Hong Kong Baptist University, Hong Kong Centre For Cerebro-Cardiovascular Health Engineering, Deep-Tech Lab, EQT Group, Gobi Partners, Hai Kang Life Corporation Limited, Grays Ferry Capital, AstraZeneca, The Johns Hopkins University, and The Hong Kong University of Science and Technology. Their education includes studies at The Johns Hopkins University and studies at University Of California, Berkeley.